<?xml version="1.0" encoding="UTF-8"?>
<ref id="B211-ijms-21-05559">
 <label>211.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>De Luca</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Cavalli</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Campochiaro</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Della-Torre</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Angelillo</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Tomelleri</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Boffini</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Tentori</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Mette</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Farina</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: A single-centre, prospective cohort study</article-title>
  <source>Lancet Rheumatol.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30170-3</pub-id>
 </element-citation>
</ref>
